ABSTRACT

Objective Opioid and benzodiazepine co-prescribing is associated with a substantial increase in opioid overdose deaths. In this study, we examine the prescribing trends of substitutes of opioids and benzodiazepines alone or in combination, compared with opioids and benzodiazepines.

Design Retrospective cohort study.

Setting Data were collected using a 20% national sample of Medicare beneficiaries from 2013 to 2018.

Participants 4.1–4.3 million enrollees each year from 2013 to 2018.

Intervention None.

Primary outcome We employ a generalised linear mixed models to calculate ORs for opioid use, benzodiazepine or Z-drug (benzos/Z-drugs) use, opioid/benzos/Z-drugs 30-day use, gabapentinoid use and (selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs)) use, adjusted for the repeated measure of patient. We then created two models to calculate the ORs for each year and comparing to 2013.

Results Opioid and benzos/Z-drugs use decreased by 2018 (aOR 0.626; 95% CI 0.622 to 0.630) comparing to 2013. We demonstrate a 36.3% and 9.9% increase in the rate of gabapentinoid and SSR/SNRI use, respectively. Furthermore, combined gabapentinoid and SSR/SNRI use increased in 2018 (aOR 1.422; 95% CI 1.412 to 1.431).

Conclusion Little is known about the prescribing pattern and trend of opioid and benzodiazepine alternatives as alternatives. There is a modest shift from prescribing opioid and benzos/Z-drugs (alone or in combination) towards prescribing non-opioid alternatives—gabapentinoids with and without non-benzos/Z-drugs that are indicated for anxiety. It is unclear if this trend towards opioid/benzos/Z-drugs alternatives is associated with fewer drug overdose death, better control of pain and comorbid anxiety, and improved quality of life.

INTRODUCTION

Opioid use contributes to over two-thirds of drug overdose-related deaths in the USA. This finding prompted the US Drug Enforcement Administration, the Centers for Disease Control and Prevention (CDC), state governments and health payers to implement policies and guidelines limiting prescriptions of opioid analgesics, especially for noncancer pain. Following the publication of these guidelines, there has been a decrease in the overall number of opioid prescriptions, including a 54% decline in initial opioid prescription between 2012 and 2017.

Risks of opioid overdose and related hospitalisations are increased with concurrent use of benzodiazepines and other central nervous system depressants. Both drug classes can be sedating, suppress respiratory efforts, impair thought, slow response time and increase falls. Several studies described the trend in concomitant use of benzodiazepines with prescription opioids prior to the 2016 CDC guidelines. For example, Sun et al described an increase in the rate of co-prescribed opioids and benzodiazepine in privately insured enrollees, from 9% in 2001 to 17% in 2013. This trend in co-prescribing came with a substantial increase in the risk of both fatal and nonfatal opioid overdose. In 2016, the CDC published a guideline for all clinicians to ‘avoid concurrent opioid and benzodiazepine prescribing’. Following the
CDC guideline, several studies have reported a decrease in opioid and benzodiazepine co-prescribing. For example, Wang et al reported more than 15% relative reduction in the number of recipients with opioid/benzodiazepines overlapping prescription from 2012 to 2017.

In parallel with decline in opioid use, gabapentinoids are increasingly being prescribed by clinicians as a potential alternative to opioid analgesics, with gabapentinoids prescribing rate rising since the 2016 CDC opioid-prescribing guideline for chronic pain. Patients with chronic pain have a high rate of co-occurrence of anxiety disorders for which benzodiazepines are frequently prescribed, a prescribing practice associated with high risk of opioid overdose death. While the prevalence of anxiety disorders vary according to the sources of chronic pain—back pain versus abdominal pain, McWilliams et al showed a 35.1% prevalence of anxiety disorders among the community-dwelling participants of the US National Comorbidity Survey who reported chronic pain, a rate of almost twice that of anxiety disorder prevalence (18.1%) in the control general population. It is unclear the extent to which clinicians have shifted from benzodiazepine prescribing to guideline-recommended serotonergic anxiolytics as alternative drug for the comorbid anxiety disorders in chronic pain patients. The most common serotonergic anxiolytics are the selective serotonin reuptake inhibitors (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI), and because of their safety profile even in overdose, they are possible substitutes for benzodiazepines in patients with co-occurring anxiety and pain.

There are no studies on whether the use of potential substitute drugs (gabapentinoids and SSRIs/SNRIs) increased as opioids and benzodiazepines decreased. We hypothesised that opioid and benzodiazepine prescriptions would decrease while substitute medications, gabapentinoids and SSRIs/SNRIs, would increase in response to the published and widely disseminated 2016 CDC opioid and benzodiazepine guidelines. We thus examined the correlates and time trends—from 2013 to 2018—in prescribing of opioids, benzodiazepines, gabapentinoids and SSRIs/SNRIs alone and in combinations among Medicare beneficiaries, before and after the 2016 CDC guideline.

**METHODS**

**Source of data**

Data were collected using a 20% national sample of Medicare beneficiaries from 2013 to 2018, from which cohorts for each year were created. Beneficiaries were excluded from a yearly cohort if they did not have Medicare parts D coverage for the entire calendar year or until death. We further excluded beneficiaries who did not have part A and B coverage or have HMO coverage that year or in the prior year (see online supplemental etable 1; online supplemental results).

**Study outcomes**

The outcomes were prescriptions for opioids, benzodiazepines or Z-drugs, gabapentinoids or SSRIs/SNRIs during the calendar year. Consistent with past research, we chose to combine Z-drugs and benzodiazepines because of their shared actions as benzodiazepine receptor agonists, with overlapping side effect profiles. While we recognise that some pharmacodynamic/kinetic differences exist among the constituent drugs comprising benzodiazepine receptor agonist drug group (eg, chlorzepoxide vs alprazolam; zolpidem vs zaleplon) and the SSRIs/SNRIs drug group (fluoxetine vs paroxetine vs duloxetine), benzodiazepines and Z-drugs are henceforth referred to as benzos/Z-drugs while the serotonergic agents are referred to as SSRIs/SNRIs, a reflection of shared mechanisms and toxicity profile by drugs in each group. Gabapentinoids comprise pregabalin and gabapentin and are henceforth referred to as GABA. We calculated the proportion of the population in each year that had any filled prescription of each of the drugs alone, as well as the following combinations: opioids and benzos/Z-drugs, opioids and SSRIs/SNRIs, GABA and benzos/Z-drugs, GABA and SSRIs/SNRIs. We also calculated the proportion of the population with 30-day combination prescriptions of opioids and benzos/Z-drugs or GABA and benzos/Z-drugs.

**Study measures**

The main independent variable was year, first with each year considered as a categorical variable and then as a dichotomised variable (2013/2014 vs 2017/2018 representing years before and after the publication of the CDC guideline). Other variables included age (<65, 65–74, 75–84, ≥85), sex (male, female), race (white, black, Asian, Hispanic, other), number of elixhauser comorbidities (no comorbidities, ≤0, 1–5, 6–10, 11–15, ≥16), original reason for Medicare entitlement (disabled/ESRD or old

![Figure 1](https://www.bmj.com/figures/bmjopen-2021-053487/figure1.png)
**RESULTS**

The characteristics of the study cohorts are described in Supplementary Table 2. The study cohort included 4.1–4.3 million enrollees each year from 2013 to 2018; 59.4% of the enrollees were female; 38.7% in the 65 to <75 age group and 79.6% were white. While 31% beneficiaries lacked comorbidities; 12.3% of the cohort had 15+ comorbidities. Our sample comprised 27.6% with disability as original reason for Medicare entitlement and 30.1% who had Medicaid dual eligibility (see online supplementary eTable 2).

**Table 1** Analysis of the odds of receiving a prescription for opioids, benzos/Z-drugs, gabapentin or SSRI/SNRI: 2013–2018

<table>
<thead>
<tr>
<th>Year</th>
<th>Benzos/Z-drugs</th>
<th>GABA</th>
<th>Opioid</th>
<th>SSRI/SNRI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Model 1*</td>
<td>Model 2†</td>
<td>Model 1</td>
<td>Model 2</td>
</tr>
<tr>
<td>2013</td>
<td>REF</td>
<td>REF</td>
<td>REF</td>
<td>REF</td>
</tr>
<tr>
<td>2014</td>
<td>0.951 (0.948, 0.954)</td>
<td>1.085 (1.081, 1.090)</td>
<td>0.977 (0.974, 0.980)</td>
<td>1.026 (1.022, 1.029)</td>
</tr>
<tr>
<td>2015</td>
<td>0.924 (0.921, 0.927)</td>
<td>1.164 (1.159, 1.169)</td>
<td>0.941 (0.938, 0.944)</td>
<td>1.044 (1.041, 1.048)</td>
</tr>
<tr>
<td>2016</td>
<td>0.874 (0.871, 0.876)</td>
<td>1.255 (1.249, 1.260)</td>
<td>0.893 (0.890, 0.895)</td>
<td>1.067 (1.063, 1.070)</td>
</tr>
<tr>
<td>2017</td>
<td>0.819 (0.816, 0.821)</td>
<td>1.322 (1.326, 1.337)</td>
<td>0.823 (0.821, 0.826)</td>
<td>0.780 (0.778, 0.782)</td>
</tr>
<tr>
<td>2018</td>
<td>0.758 (0.755, 0.760)</td>
<td>1.363 (1.358, 1.369)</td>
<td>0.721 (0.719, 0.723)</td>
<td>1.099 (1.095, 1.102)</td>
</tr>
</tbody>
</table>

*Model 1: year, age, sex, race, elixhauser comorbidity, disability, dual eligibility, PCP, metro, region, all interactions.
†Model 2: year (dichotomous 2013/2014 vs 2017/2018), age, sex, race, elixhauser comorbidity, disability, dual eligibility, PCP, metro, region.
‡2013/2014 used as reference (1.00), comparing years before (2013/2014) vs after (2017/2018) the publication of the CDC guideline.

CDC, Centers for Disease Control and Prevention; GABA, gabapentinoids (pregabalin and gabapentin); PCP, Primary Care Physician; REF, reference=1; SNRIs, serotonin norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors.
drugs for 30 days: opioid plus benzos/Z-drugs; opioid plus SSRIs/SNRIs; GABA plus benzos/Z-drugs; and GABA plus SSRIs/SNRIs. The percentage receiving opioids plus benzos/Z-drugs was 7.5% in 2013 and declined to 4.7% in 2018. The percent prescribed both opioid and SSRIs/SNRIs was 7.4% in 2013 vs 5.7% in 2018. The percentage of enrollees concurrently prescribed GABA and benzos/Z-drugs was relatively unchanged, from 3.6% in 2013 to 3.4% in 2018. GABA and SSRIs/SNRIs increased from 4.2% in 2013 to 5.4% in 2018.

Table 2 depicts time trends of 30-day use of coprescribed drugs. Coprescribed opioid and benzos/Z-drugs decreased in use by 2018 (aOR 0.626; 95% CI 0.622 to 0.630) comparing to 2013 and the 2017/2018 comparing to 2013/2014 (aOR 0.700; 95% CI 0.697 to 0.703). Combined GABA and SSRIs/SNRIs increased in use in 2018 (aOR 1.422; 95% CI 1.412 to 1.431) and in 2017/2018 (aOR 1.335; 95% CI 1.329 to 1.341). Other characteristics associated with coprescribing of each combination were included in online supplemental etable 4.

**DISCUSSION**

In this retrospective study using a national sample of Medicare beneficiaries data from 2013 to 2018, we found a decrease in the rate of prescribing of opioids and benzos/Z-drugs, and an increase in the rate of gabapentinoid prescribing. Combined opioid and benzos/Z-drugs prescriptions decreased as did combined opioid and SSRIs/SNRIs coprescription, while gabapentinoids and SSRIs/SNRIs coprescription increased. The rate of combined gabapentinoid and benzos/Z-drugs coprescription remained stable throughout the study period.

The time trends in prescribing rates of opioids, benzos/Z-drugs, gabapentinoids and SSRIs/SNRIs alone and in combination before and after the CDC guidelines were uniform across all genders, racial and ethnic groups, and geographic locations. Our findings on the
changes in prescribing rates of opioid, benzos/Z-drugs, gabapentinoids and SSRIs/SNRIs, either individually or in combination from 2013 to 2018, suggests a change in prescribers’ behaviour. One possible explanation for the change in prescribers’ practice could be the potential effects of the widely disseminated 2016 CDC guideline along with subsequent policies by state governments and health payers regulating opioid and benzodiazepine prescribing.

Our study demonstrated a gradual decrease in individually prescribed opioids and benzos/Z-drugs from 2013 to 2016 (figure 1). This early decrease corresponds with the 2013 implementation of the Opioid Safety Initiative, a Veterans Health Administration initiative to reduce high-dose opioids, and the 2014 DEA hydrocodone rescheduling policy. Our finding showed that the decrease continued in both benzos/Z-drugs and opioid prescribing for another 2 years after the 2016 CDC guidelines that were widely disseminated to all clinicians in the USA. This finding is consistent with previous studies.8 17 18 The pattern of decline in both opioid and benzos/Z-drugs prescribing rates suggests caution on the part of prescribers, considering the well-documented toxicities and risks of both drugs.11–16

Individually prescribed gabapentinoid increased by more than 36.3% during the study period (2013–2018), with a smaller increase observed in SSRIs/SNRIs prescription rates. Our finding suggests that prescribers are using non-opioid (gabapentinoids) and non-benzos/Z-drugs (SSRIs/SNRIs) substitutes as alternatives to treat chronic pain and anxiety. Previous studies have reported on the potential for non-opioid analgesics in decreasing over-prescription of opioids for chronic non-cancer pain and in mitigating pre-existing opioid use disorders.25 26 We were surprised that we did not observe a more substantial increase in both gabapentinoids and SSRIs/SNRIs prescribing overtime, which suggest insufficient evidence to guide clinicians on the effectiveness and safety of these drugs. Further research is urgently needed to provide data on effects of these drugs on decreasing pain and anxiety, and increasing function and quality of life of patients with chronic pain and comorbid anxiety disorders. More research is also needed on best approaches to managing all the five major types of anxiety disorder—generalised anxiety disorder, obsessive–compulsive disorder, panic disorder and social anxiety disorders—which are common in chronic pain patients and are contributors to excess disability in these patients.24

We found that the 30-day co-prescribing of opioids with benzos/Z-drugs decreased from 2013 to 2016, before the publication of the 2016 CDC guidelines, and continued thereafter through 2018, a finding similar to a study by Bohnert et al, based on retail pharmacy data from 2015 to 2017 but different from Jeffery et al who described an increase or stabilisation of co-prescribing rates prior to the CDC guidelines. This difference could be due to inherent differences in the study populations observed. Jeffery et al included people who were commercially insured or had Medicare Advantage. The difference may also be a reflection of differences in study design. We reported trends from 2013 to 2018 of co-prescribed opioid and benzos/Z-drugs each year while Jeffery et al separately reported trends in the first 90 days in commercially insured beneficiaries. Jeffery et al did, however, find a decrease in trend in the first 90 days in the subset of Medicare Advantage enrollees. Our study findings thus extend decrease in opioid-benzos/Z-drugs coprescribing that occurs in the immediate aftermath of the 2016 CDC guideline to 2 years thereafter with a concomitant increase in prescribing of non-opioid and non-benzos/Z-drugs alternatives, a direction that is consistent with a recognition of the adverse effects associated with opioids and benzos/Z-drugs coprescribing related accidents, injuries and deaths.11–16 18 35–37

Our finding of increase in the use of combined gabapentinoid and SSRIs/SNRIs from 2013 to 2018 suggest some shift by clinicians to considering alternatives to opioids and benzodiazepines, despite lack of comparative effectiveness and safety data on the use of benzos/Z-drugs and opioid substitutes in the context of chronic pain syndrome and comorbid anxiety disorders; this is clearly an area for future investigations. We used the year 2013 as the reference time point in our analysis of subsequent time points. The odds of receiving a long-term prescription (up to 30 days) of both gabapentin and SSRIs/SNRIs increased in 2018. We also analysed dichotomous years before (2013/2014) and after (2017/2018) 2016. The release of the CDC guidelines was associated with an increase in use of substitute drugs, gabapentinoids, and SSRIs/SNRIs (adjusted odds ratio (aOR) 1.335; 95% CI 1.329 to 1.341) compared with opioid and benzos/Z-drugs (aOR 0.700; 95% CI 0.697 to 0.703). Whether this trend continues beyond 2018 remains to be seen.

There were limitations in our study. First, our study included individuals who filled prescriptions. Using that data, we were unable to verify whether the patients actually took the prescribed drugs, considering that diversion of prescribed opioids and benzos/Z-drugs is a rising concern in the USA. This limitation is generally present in pharmacoepidemiological analyses performed using administrative claims data. Second, these results are only representative of Medicare part D beneficiaries and not HMO or Medicare Advantage or commercially insured patients. Third, the enrollees under age 65 were highly selected and enrolled because of either disability or end-stage renal disease (ESRD) and are thus not representative of the general population under 65 years of age. Fourth, given the large sample size of our study with more than 4 million enrollees per year, even very small differences will be statistically significant, and these may not have substantial clinical significance. We were, therefore, more interested in clinical significance and emphasised results with large effect size. Lastly, the results presented in this study do not assess prescriber factors and outcomes associated with co-prescribing of opioid, benzodiazepine,
gabapentinoids and SSRI/SNRIs—an area for future investigation.

In summary, we demonstrated an increase in coprescribed gabapentinoids and SSRIs/SNRIs trend across the study period. The increasing use of opioid and benzos/Z-drugs substitutes could reflect a gradual shift in patterns of managing pain and comorbid anxiety disorders, from opioid/benzos/Z-drugs to alternatives that clinicians consider as being safer—despite no high-level evidence. The modest increase in our observed time trends could also reflect the uncertainty in toxicity profile of gabapentinoids and SSRIs/SNRIs trend across the prolonged period—perhaps a reflection of paucity of comparative toxicity data. The long-term toxicity profile of coprescribed gabapentinoids and SSRIs/SNRIs remains to be elucidated. Reduction in the percentage of patients who received prescriptions for benzos/Z-drugs or opioids, either alone or in combination, conveys a potential shift in the prescribing behaviours towards substitute medication for pain and anxiety. It is, however, not clear if these shifts in prescribing behaviour are associated with good pain and anxiety control, fewer toxicities and better quality of life for patients living with chronic pain and comorbid anxiety.

Author affiliations
1Neurology, The University of Texas Medical Branch, Galveston, Texas, USA
2Division of Geriatrics and Palliative Medicine & Sealy Center on Aging, Department of Internal Medicine, The University of Texas Medical Branch, Galveston, Texas, USA
3Division of Geriatrics and Palliative Medicine & Sealy Center on Aging, Department of Internal Medicine, Department of Preventive Medicine and Population Health, Institute for Translational Science, The University of Texas Medical Branch, Galveston, Texas, USA
4Office of Biostatistics, The University of Texas Medical Branch, Galveston, Texas, USA
5Department of Neurology, Division of Geriatrics and Palliative Medicine & Sealy Center on Aging, Department of Internal Medicine, Department of Preventive Medicine and Population Health, The University of Texas Medical Branch, Galveston, Texas, USA

Contributors MAR had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: MAR, Y-FK, AE, JSS and JW. Acquisition, analysis or interpretation of data: MAR, Y-FK, AE, JSS, JG and JW. Drafting of the manuscript: MAR, Y-FK, AE, JSS and JW. Critical revision of the manuscript for important intellectual content: MAR, Y-FK, AE, JSS and JW. Statistical analysis: Y-FK and JW. Obtained funding: Y-FK and MAR. Administrative, technical or material support: MAR and Y-FK. Supervision: Y-FK, MAR and JG.

Funding This work was supported by National Institute on Drug Abuse, National Institute of Health, grant number R01-DA039192.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval The institutional review board of the University of Texas Medical Branch approved this study and waived the need for informed consent because the data were deidentified. IRB#: 16-0247.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Mukaila A Raji http://orcid.org/0000-0002-7460-7281

REFERENCES


